These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 3444015)

  • 1. [Antimicrobial activity of sulbactam/cefoperazone. Comparison with other new cephems].
    Deguchi K; Yokota N; Koguchi M; Fukayama S; Nishimura Y; Nakane Y; Oda S; Tanaka S; Kato M; Sato K
    Jpn J Antibiot; 1987 Oct; 40(10):1752-61. PubMed ID: 3444015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of sulbactam on the activity of cefoperazone against various clinical isolates].
    Uete T; Matsuo K
    Jpn J Antibiot; 1989 Apr; 42(4):896-909. PubMed ID: 2769941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. I. Effect of sulbactam against beta-lactams resistant strains and in vitro combined effect of sulbactam/cefoperazone with each of piperacillin, latamoxef, ceftazidime, fosfomycin and doxycycline].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1990 Apr; 43(4):636-58. PubMed ID: 2199689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Synergy between sulbactam and ampicillin or cefoperazone in antimicrobial activity against beta-lactamase producing microorganisms. Results with the use of microdilution broth method].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukushima Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Sato K
    Jpn J Antibiot; 1990 Jul; 43(7):1214-24. PubMed ID: 2232151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical laboratory approach for estimating effective administrative dose of sulbactam/cefoperazone].
    Uete T; Matsuo K
    Jpn J Antibiot; 1988 Nov; 41(11):1578-90. PubMed ID: 3210296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro antibacterial activity of cefoperazone].
    Watanabe Y; Minami S; Yotsuji A; Araki H; Yasuda T; Saikawa I
    Jpn J Antibiot; 1983 Dec; 36(12):3437-43. PubMed ID: 6609251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Studies on sulbactam/cefoperazone in the field of pediatrics].
    Iwai N; Taneda Y; Shibata M; Mizoguchi F; Katayama M
    Jpn J Antibiot; 1984 Oct; 37(10):1859-79. PubMed ID: 6094865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].
    Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T
    Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fundamental and clinical studies of sulbactam/cefoperazone in the pediatric field].
    Motohiro T; Tanaka K; Koga T; Shimada Y; Tomita N; Sakata Y; Fujimoto T; Nishiyama T; Ishimoto K; Tominaga K
    Jpn J Antibiot; 1984 Oct; 37(10):1898-918. PubMed ID: 6094868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fundamental and clinical studies of sulbactam/cefoperazone in the pediatric field].
    Iwata S; Sato Y; Iwasaki Y; Hayano S; Wakabayashi R; Kojima Y; Akita H; Sunakawa K; Oikawa T; Osano M
    Jpn J Antibiot; 1984 Oct; 37(10):1831-45. PubMed ID: 6094863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1982). I. Susceptibility distribution].
    Kosakai N; Igari J; Kumamoto Y; Sakai S; Nishio A; Nagai T; Shigeta S; Shiraiwa Y; Abe K; Tazaki H
    Jpn J Antibiot; 1984 Apr; 37(4):680-722. PubMed ID: 6433064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro antibacterial activity of cefoperazone-sulbactam].
    Zhang Y; Zhang J; Zhou L
    Zhonghua Nei Ke Za Zhi; 1995 Oct; 34(10):676-9. PubMed ID: 8731829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1991 Feb; 44(2):130-9. PubMed ID: 2041154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Basic and clinical evaluation of sulbactam/cefoperazone in the field of pediatrics].
    Toyonaga Y; Kurosu Y; Nakamura H; Sugita M; Takahashi T; Hori M
    Jpn J Antibiot; 1984 Dec; 37(12):2457-77. PubMed ID: 6098740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Laboratory and clinical study of sulbactam/cefoperazone (SBT/CPZ) on bacterial prostatitis].
    Suzuki K; Horiba M
    Hinyokika Kiyo; 1991 Oct; 37(10):1333-43. PubMed ID: 1755429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibacterial activities of new cephems against clinically isolated organisms (author's transl)].
    Okada K; Kawamura N; Ohkoshi M; Satake Y; Kawakita J
    Jpn J Antibiot; 1982 Apr; 35(4):1009-21. PubMed ID: 6285019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Laboratory and clinical studies of sulbactam/cefoperazone in the pediatric field].
    Nishimura T; Tabuki K; Takashima T; Takagi M
    Jpn J Antibiot; 1984 Oct; 37(10):1880-92. PubMed ID: 6094866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF; Wildfeuer A
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on the combined effect of fosfomycin with sulbactam/cefoperazone on methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa].
    Niida M; Yoshida T; Kohmoto A; Ogawa M; Hashimoto H; Deguchi K
    Jpn J Antibiot; 1994 Jan; 47(1):1-10. PubMed ID: 8114267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.